{
  "symbol": "UNH",
  "year": 2022,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1858,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.253
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) March 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 25,482 $ 21,375 Short-term investments 2,914 2,532 Accounts receivable, net 18,871 14,216 Other current receivables, net 11,994 13,866 Assets under management 4,155 4,449 Prepaid expenses and other current assets 5,613 5,320 Total current assets 69,029 61,758 Long-term investments 42,353 43,114 Property, equipment and capitalized software, net 9,183 8,969 Goodwill 77,548 75,795 Other intangible assets, net 9,918 10,044 Other assets 13,207 12,526 Total assets $ 221,238 $ 212,206 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 28,676 $ 24,483 Accounts payable and accrued liabilities 25,058 24,643 Short-term borrowings and current maturities of long-term debt 6,697 3,620 Unearned revenues 2,675 2,571 Other current liabilities 25,064 22,975 Total current liabilities 88,170 78,292 Long-term debt, less current maturities 40,796 42,383 Deferred income taxes 2,954 3,265 Other liabilities 11,671 11,787 Total liabilities 143,591 135,727 Commitments and contingencies (Note 5) Redeemable noncontrolling interests 1,519 1,434 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 939 and 941 issued and outstanding 10 10 Retained earnings 78,782 77,134 Accumulated other comprehensive loss ( 6,026 ) ( 5,384 ) Nonredeemable noncontrolling interests 3,362 3,285 Total equity 76,128 75,045 Total liabilities, redeemable noncontrolling interests and equity $ 221,238 $ 212,206 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended March 31, (in millions, except per share data) 2022 2021 Revenues: Premiums $ 64,070 $ 55,486 Products 9,340 8,340 Services 6,372 5,918 Investment and other income 367 452 Total revenues 80,149 70,196 Operating costs: Medical costs 52,523 44,904 Operating costs 11,401 10,223 Cost of products sold 8,487 7,572 Depreciation and amortization 788 758 Total operating costs 73,199 63,457 Earnings from operations 6,950 6,739 Interest expense ( 433 ) ( 397 ) Earnings before income taxes 6,517 6,342 Provision for income taxes ( 1,369 ) ( 1,364 ) Net earnings 5,148 4,978 Earnings attributable to noncontrolling interests ( 121 ) ( 116 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,027 $ 4,862 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 5.34 $ 5.14 Diluted $ 5.27 $ 5.08 Basic weighted-average number of common shares outstanding 941 945 Dilutive effect of common share equivalents 13 12 Diluted weighted-average number of common shares outstanding 954 957 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 2 3 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended March 31, (in millions) 2022 2021 Net earnings $ 5,148 $ 4,978 Other comprehensive loss: Gross unrealized losses on investment securities during the period ( 2,023 ) ( 764 ) Income tax effect 465 174 Total unrealized losses, net of tax ( 1,558 ) ( 590 ) Gross reclassification adjustment for net realized gains included in net earnings ( 3 ) ( 7 ) Income tax effect 1 2 Total reclassification adjustment, net of tax ( 2 ) ( 5 ) Total foreign currency translation gains (losses) 918 ( 417 ) Other comprehensive loss ( 642 ) ( 1,012 ) Comprehensive income 4,506 3,966 Comprehensive income attributable to noncontrolling interests ( 121 ) ( 116 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 4,385 $ 3,850 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Nonredeemable Noncontrolling Interests Total Equity Three months ended March 31, (in millions) Shares Amount Net Unrealized Gains (losses) on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2022 941 $ 10 $ \u2014 $ 77,134 $ 423 $ ( 5,807 ) $ 3,285 $ 75,045 Net earnings 5,027 88 5,115 Other comprehensive (loss) income ( 1,560 ) 918 ( 642 ) Issuances of common stock, and related tax effects 3 \u2014 333 333 Share-based compensation 282 282 Common share repurchases ( 5 ) \u2014 ( 484 ) ( 2,016 ) ( 2,500 ) Cash dividends paid on common shares ($ 1.45 per share) ( 1,363 ) ( 1,363 ) Redeemable noncontrolling interests fair value and other adjustments ( 131 ) ( 131 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 91 91 Distribution to nonredeemable noncontrolling interests ( 102 ) ( 102 ) Balance at March 31, 2022 939 $ 10 $ \u2014 $ 78,782 $ ( 1,137 ) $ ( 4,889 ) $ 3,362 $ 76,128 Balance at January 1, 2021 946 $ 10 $ \u2014 $ 69,295 $ 1,336 $ ( 5,150 ) $ 2,837 $ 68,328 Net earnings 4,862 80 4,942 Other comprehensive loss ( 595 ) ( 417 ) ( 1,012 ) Issuances of common stock, and related tax effects 3 \u2014 256 256 Share-based compensation 242 242 Common share repurchases ( 5 ) \u2014 \u2014 ( 1,650 ) ( 1,650 ) Cash dividends paid on common shares ($ 1.25 per share) ( 1,181 ) ( 1,181 ) Redeemable noncontrolling interests fair value and other adjustments ( 498 ) ( 106 ) ( 604 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 66 66 Distribution to nonredeemable noncontrolling interests ( 74 ) ( 74 ) Balance at March 31, 2021 944 $ 10 $ \u2014 $ 71,220 $ 741 $ ( 5,567 ) $ 2,909 $ 69,313 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, (in millions) 2022 2021 Operating activities Net earnings $ 5,148 $ 4,978 Noncash items: Depreciation and amortization 788 758 Deferred income taxes 161 341 Share-based compensation 299 256 Other, net 17 ( 55 ) Net change in other operating items, net of effects from acquisitions and changes in AARP balances: Accounts receivable ( 4,521 ) ( 2,895 ) Other assets ( 1,089 ) ( 955 ) Medical costs payable 3,849 2,968 Accounts payable and other liabilities 589 870 Unearned revenues 78 ( 261 ) Cash flows from operating activities 5,319 6,005 Investing activities Purchases of investments ( 4,982 ) ( 4,612 ) Sales of investments 1,591 643 Maturities of investments 1,759 2,255 Cash paid for acquisitions, net of cash assumed ( 1,231 ) ( 1,193 ) Purchases of property, equipment and capitalized software ( 555 ) ( 568 ) Other, net ( 255 ) ( 232 ) Cash flows used for investing activities ( 3,673 ) ( 3,707 ) Financing activities Common share repurchases ( 2,500 ) ( 1,650 ) Cash dividends paid ( 1,363 ) ( 1,181 ) Proceeds from common stock issuances 551 436 Repayments of long-term debt ( 1,100 ) ( 1,150 ) Proceeds from short-term borrowings, net 3,148 4,057 Customer funds administered 5,120 2,131 Other, net ( 1,552 ) ( 1,856 ) Cash flows from financing activities 2,304 787 Effect of exchange rate changes on cash and cash equivalents 157 ( 51 ) Increase in cash and cash equivalents 4,107 3,034 Cash and cash equivalents, beginning of period 21,375 16,921 Cash and cash equivalents, end of period $ 25,482 $ 19,955 See Notes to the Condensed Consolidated Financial Statements 5 Table of Contents UnitedHealth Grou\n1 $ ( 397 ) $ 6,342 12 Table of Contents ITEM\u00a02.",
      "score": 0.9976
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2022 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 578 $ 202 $ (3,090) $ (7,429) 1 289 101 (1,586) (4,041) (1) (92) (46) 1,650 4,857 (2) (92) (46) 3,280 10,710 Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of March 31, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 and 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero.",
      "score": 0.9828
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2022 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 578 $ 202 $ (3,090) $ (7,429) 1 289 101 (1,586) (4,041) (1) (92) (46) 1,650 4,857 (2) (92) (46) 3,280 10,710 Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of March 31, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 and 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero.",
      "score": 0.9828
    }
  ],
  "top_negative": [
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "2021 Revenues: Premiums $ 64,070 $ 55,486 $ 8,584 15 % Products 9,340 8,340 1,000 12 Services 6,372 5,918 454 8 Investment and other income 367 452 (85) (19) Total revenues 80,149 70,196 9,953 14 Operating cost\noutlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We will continue seeking to balance growth and profitability across all these dimensions."
  ]
}